Growth factor

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Retrieved on:

星期三, 五月 29, 2024

Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2024:

Key Points:

Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2024:
Cash Position: As of March 31, 2024, Immunovant’s cash and cash equivalents totaled approximately $635 million.
Financial Highlights for Fiscal Year Ended March 31, 2024:
R&D Expenses: Research and development expenses were $212.9 million for the fiscal year ended March 31, 2024, compared to $160.3 million for the fiscal year ended March 31, 2023.
G&A Expenses: General and administrative expenses were $57.3 million for the fiscal year ended March 31, 2024, compared to $48.0 million for the fiscal year ended March 31, 2023.
Net loss for the fiscal year ended March 31, 2024 and 2023 included $41.1 million and $32.3 million, respectively, related to non-cash stock-based compensation expense.

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors

Retrieved on:

星期一, 四月 1, 2024

Culture, EGFR, Organization, Philosophy, Education, History, Patient, Orphan, Left–right political spectrum, Growth factor, Acquisition, Perrigo, Quality of life, Psychology, Drug development, TEL, Food, Pharmaceutical industry

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Key Points:

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
"Mori is one of Israel's most successful life sciences and pharmaceutical entrepreneurs with an extraordinary background spanning decades in the industry," stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma.
"Arkin Bio Ventures has been an investor in Lutris Pharma since its inception and has been a steadfast supporter of the Company, ever since.
In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors

Retrieved on:

星期一, 四月 1, 2024

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Key Points:

TEL AVIV, Israel, April 1, 2024 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the appointment Moshe "Mori" Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.
"Mori is one of Israel's most successful life sciences and pharmaceutical entrepreneurs with an extraordinary background spanning decades in the industry," stated Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma.
"Arkin Bio Ventures has been an investor in Lutris Pharma since its inception and has been a steadfast supporter of the Company, ever since.
In 2011, they formed the Arkin Family Foundation, which supports organizations and projects in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

Retrieved on:

星期一, 二月 5, 2024

Growth factor, Patient, IND, Safety, FDA, EGFR, Food, Trial of the century, Neoplasm, Malignancy, ACC, Pharmaceutical industry

ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors.

Key Points:

ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors.
Phase 1 Clinical Study Expected to Begin in H2 2024.
This clearance enables Acepodia to initiate a Phase 1, first-in-human trial evaluating the safety, tolerability and pharmacodynamics of ACE2016 in adults with locally advanced or metastatic EGFR-expressing solid tumors.
Acepodia expects to begin the trial in the coming months and treat the first patient in the second half of 2024.

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

Retrieved on:

星期二, 十二月 5, 2023

TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.

Key Points:

TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.
Throughout these studies umedaptanib pegol was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment.
In nAMD patients with a long history of anti-VEGF treatment, umedaptanib pegol showed no additional benefit of monotherapy or the combination over Eylea®.
Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study.

Bradford Airport Logistics Announces Significant Strategic Equity Investment from Bregal Sagemount to Support Growth

Retrieved on:

星期二, 九月 12, 2023

Bradford Airport Logistics (“Bradford” or the “Company”), a leading provider of advanced logistics services to airports and other transportation hubs through its proprietary Centralized Receiving and Distribution Centers (“CRDC”) model, today announced that it received a significant growth equity investment from Bregal Sagemount (“Sagemount”), a leading private equity platform with a focus on growth investments in the United States and Europe.

Key Points:

Bradford Airport Logistics (“Bradford” or the “Company”), a leading provider of advanced logistics services to airports and other transportation hubs through its proprietary Centralized Receiving and Distribution Centers (“CRDC”) model, today announced that it received a significant growth equity investment from Bregal Sagemount (“Sagemount”), a leading private equity platform with a focus on growth investments in the United States and Europe.
The investment will help Bradford pursue enhanced domestic growth opportunities, deploy a new global-growth initiative, and support capabilities in Design-Build-Finance-Operate-Manage models for CRDCs.
"We are thrilled to welcome the talented Sagemount team during an exciting period of growth.
The investment was further supported by Curt Witte, Partner and Head of Growth Factors, and members of the Growth Factors team.

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Retrieved on:

星期一, 八月 14, 2023

Monoclonal antibody, Growth factor, CD3, Neoplasm, CCR4, Head, Breast, CCR8, Antibody, Doctor of Philosophy, Lung, Animal, Cancer, SAN, EGFR, Carcinoma, IND, Vaccine, Pharmaceutical industry

BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced positive pre-clinical in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage.

Key Points:

In preclinical studies, iBio’s anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.
iBio developed the antibody using its patented AI epitope steering technology.
By focusing solely on the tumor-specific variant, iBio aims to reduce potential side effects.
In addition to the anti-EGFR program, iBio’s CCR8 antibody has proven effective in a mouse model for colon cancer.

EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients

Retrieved on:

星期四, 六月 8, 2023

National Institute on Drug Abuse, Hebrew University of Jerusalem, Al-Quds, Cancer, Quality of life, Research, Signal transduction, Rash, Patient, EGFR, Hadassah Medical Center, NGT, Financial toxicity, Skin, Growth factor, Pharmaceutical industry

JERUSALEM, June 8, 2023 /PRNewswire/ -- Hadasit, and Yissum, has spun off EMRIS Pharma in collaboration with NGT Healthcare2 VC. EMRIS Pharma is pioneering novel small molecule-based topical compounds that can improve both quality of life and treatment compliance for cancer patients. Based on over ten years of research collaboration by the founders, Dr. Sharon Merims, a senior dermatologist specializing in dermato-oncology at the Hadassah Medical Center, and Professor Ofra Benny from the Institute for Drug Research at the Hebrew University of Jerusalem, and with the support of NGT Healthcare2 VC, the company's first product aims to treat the skin toxicities caused by EGFRi (Epidermal Growth Factor Receptor inhibitors). Many of the molecularly targeted agents used in current cancer treatments, particularly those interfering with signal transduction EGFRi and small molecule tyrosine kinase inhibitors, are associated with papulopustular skin rash. This rash is observed in ~90% of patients receiving EGFR-targeted monoclonal antibodies, and often impacts the patient's quality of life, and the ability to continue the cancer treatment. Dr. Merims will serve as EMRIS Pharma's Chief Scientific Officer, and Professor Benny as the company's Chief Technology Officer.

Key Points:

EMRIS Pharma is pioneering novel small molecule-based topical compounds that can improve both quality of life and treatment compliance for cancer patients.
This rash is observed in ~90% of patients receiving EGFR-targeted monoclonal antibodies, and often impacts the patient's quality of life, and the ability to continue the cancer treatment.
Their novel approach to managing skin toxicities caused by EGFR inhibitors has the potential to significantly improve the quality of life for cancer patients and increase treatment compliance.
We believe that EMRIS Pharma's innovative research and development will lead to a brighter future for cancer patients, and we look forward to supporting their mission."

Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China

Retrieved on:

星期二, 四月 11, 2023

CE, Marketing, Agency agreement, Gunze, Growth factor, Shenzhen, Trauma, Patient, Neoplasm, FDA, Silk, EU

HONG KONG, Apr 11, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement ("Agency Agreement") with Gunze Medical Devices (Shenzhen) Ltd. ("Gunze Shenzhen"), a wholly-owned subsidiary of Gunze Limited ("Gunze") in Japan, for PELNAC Absorbable Dressing ("PELNAC"), for a product manufactured by Gunze.

Key Points:

HONG KONG, Apr 11, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement ("Agency Agreement") with Gunze Medical Devices (Shenzhen) Ltd. ("Gunze Shenzhen"), a wholly-owned subsidiary of Gunze Limited ("Gunze") in Japan, for PELNAC Absorbable Dressing ("PELNAC"), for a product manufactured by Gunze.
Pursuant to the Agency Agreement, Essex Medipharma will be the exclusive agent of PELNAC in Mainland China for a period of 5 years, starting from 2023 to 2027.
PELNAC, the world's leading artificial dermis product, consists of a collagen sponge layer, which provides a scaffold for cellular invasion and capillary growth, and a silicone film layer, which is reinforced with non-adhesive gauze.
PELNAC is not only available in Mainland China and Japan, but has also obtained the CE marking in the EU and FDA approval in the US.

Skinuva Launches Skinuva Scar+: Physician Developed, Solutions Driven Scar Cream with Zinc Oxide Mineral Sunscreen

Retrieved on:

星期二, 一月 24, 2023

FAAD, UVA, SPF, Hyperpigmentation, Skin cancer, Skin, Silicone, Dermatology, Sunburn, Neck, Hyaluronic acid, Ageing, Zinc, UVB, Physician, Red, DO, Face, Patient, Risk, Smash Mouth, Growth factor, Science, Cosmetics

BEVERLY HILLS, Calif., Jan. 24, 2023 /PRNewswire/ -- Skinuva is excited to announce the launch of its newest physician developed and solutions driven product, Skinuva Scar+ SPF 30.

Key Points:

BEVERLY HILLS, Calif., Jan. 24, 2023 /PRNewswire/ -- Skinuva is excited to announce the launch of its newest physician developed and solutions driven product, Skinuva Scar+ SPF 30.
Skinuva Scar+ SPF 30 is a scar photoaging defense cream using highly selective growth factors with Zinc Oxide mineral sunscreen.
Skinuva Scar+ has all the benefits of the original Skinuva Scar but with added non-nano Zinc Oxide for broad spectrum UVA/UVB protection to help improve the appearance of scars in sun-exposed areas.
"Having achieved that, we now provide the added benefits of Zinc Oxide mineral sunscreen within the same clinically proven ingredients of Skinuva Scar to help improve scars in sun-exposed areas of the skin."